Acne 

Actinic Keratosis 

Aesthetics

Allergy

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

BPDCN

COVID-19

Diabetes 

Dry Cracked Skin

Examining Nature-Based Skincare

Fibroids

Hidradentitis Suppurativa

Impetigo

Inflamed Skin

Melasma

Pediatric Dermatology

Pigmentary Disorders 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Surgery

Vitiligo

Women's Health

Wound Care

News

Device Technology

Drug Watch

Legal

Lifestyle

NP and PA

Practice Management 

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

Dermview

Editorial Board News

Expert Interviews

Expert Perspectives

Frontline Forum

Inside the Clinic

Medical World News

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

Image IQ

Interactive Tools

Job Board

Partnerships

Polls

Editorial Board

Subscribe

Print Subscription

eNewsletter

Articles

ICYMI, this week we had stories about dermatologic disparities among veterans and LGBTQIA+ patients, pediatric melanoma, a European approval for hidradenitis suppurativa, and more.

The Weekly Roundup: May 29-June 2

Researchers examined the disease while going beyond current diagnostic tools.

New Study Uncovers Cells and Pathways Driving Psoriasis Inflammation and Severity

The World Health Organization shared its enthusiasm for the “appropriate” use of these technologies. However, they are calling for caution to be exercised to protect and promote human well-being, safety, and autonomy and preserve public health.

WHO Calls For Caution When it Comes to Using AI For Health

Scientists have found a new therapy for the severe inflammatory skin disorder.

Scientists Identify Treatment Option for Rare Pansclerotic Morphea

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Anti-Aging

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

Authors

Neoadjuvant treatment with cemiplimab led to near or complete disappearance of cutaneous squamous cell carcinoma in almost 64% of patients set to undergo surgery.

Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

Kristie L. Kahl

Articles